Cargando…
Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor
Cancers are driven by a variety of somatic gene mutations and identifying these mutations enables the development of novel target drugs. We have sought to identify abnormalities in Wnt pathway-related genes that are sensitive to Wnt inhibitor treatment. We examined Patient Derived Xenograft (PDX) RN...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155119/ https://www.ncbi.nlm.nih.gov/pubmed/30250044 http://dx.doi.org/10.1038/s41598-018-32652-3 |